Phase 2 Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
|Effective start/end date||8/1/16 → 7/31/22|
- SEAGEN INC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.